MANIFEST US Study Presented as a Late-Breaking Clinical Trial at AHA

Richard E. Pratley, M.D., senior investigator and diabetes program lead at the AdventHealth Translational Research Institute (TRI), served as one of the lead researchers on the international FINE-ONE...

The CLEAR Study is a groundbreaking, international research effort funded by the NIH that aims to help people with Type 1 diabetes (T1D) who can no longer sense when their blood sugar is dangerously...

Sjögren’s disease has been recognized in adults for almost a century, first described by Swedish ophthalmologist Henrik Sjögren in the early 20th century. One of the biggest challenges in recognizing...

Heart disease is often thought of as a “man’s disease,” but it remains the leading cause of death for women in the United States. We asked Katie Love, MD, MSc, an investigator at the AdventHealth...

Understanding the connection between GLP-1 medications and hormone therapy

Why scientists are taking a closer look at why women face higher Alzheimer’s risk

A new systematic review of clinical trials has found that no single dietary pattern consistently improves blood sugar control or weight management in youth and adults living with type 1 diabetes.

What we eat has a big impact on the bacteria living in our gut, which in turn affects how our bodies use energy—something that plays a major role in the development and treatment of obesity.

AdventHealth Neuroscience Institute has launched THRIVE, an NIH-funded clinical trial led by Lauren Oberlin, PhD, geriatric neuropsychologist and neuroscience researcher.

On September 19, 2025, AdventHealth Tampa successfully enrolled its first patient in the Tectonic CAD Intravascular Lithotripsy (IVL) Trial, led by Dr. Mahmaljy and his team.

Dr. Karen Corbin, associate investigator at the AdventHealth Translational Research Institute for Metabolism and Diabetes in Orlando, emphasizes the essential role of diet in maintaining a healthy gut...

AdventHealth Research Institute (AHRI) is proud to announce that the Southeast Region’s Redmond Campus has been recognized as the top enrolling site nationally for the CARVTOP-ICD trial.